PeptiDream Inc (PPTDF)
12.80
-0.31
(-2.38%)
USD |
OTCM |
May 06, 14:43
PeptiDream Research and Development Expense (Quarterly): 6.067M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 6.067M |
| September 30, 2023 | 5.215M |
| June 30, 2023 | 5.816M |
| March 31, 2023 | 5.361M |
| December 31, 2022 | 7.282M |
| September 30, 2022 | 5.247M |
| Date | Value |
|---|---|
| June 30, 2022 | 5.939M |
| March 31, 2022 | 3.393M |
| December 31, 2021 | 5.016M |
| September 30, 2021 | 2.846M |
| June 30, 2021 | 6.947M |
| March 31, 2021 | 3.434M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
2.846M
Minimum
Sep 2021
7.282M
Maximum
Dec 2022
5.214M
Average
5.304M
Median
Research and Development Expense (Quarterly) Benchmarks
| Takeda Pharmaceutical Co Ltd | 1.269B |
| Nxera Pharma Co Ltd | 20.74M |
| Stemcell Holdings Inc | -- |
| Healios KK | 5.235M |
| AnGes Inc | 9.032M |